Print

Print


Team tests gene therapy for Parkinson's
 disease

 February 24, 1998


 Nikkei English News via Individual Inc. : Nikkei Weekly-copyright Nihon
Keizai
 Shimbun,Inc.

 Team tests gene therapy for Parkinson's disease

 A new gene therapy for Parkinson's disease has been developed by a
research team
 from Nagoya City University, the Institute of Physical and Chemical
Research, and
 Fujita Health University. The team reports some success with animal
experiments and
 aims to refine the technique to move on to human clinical tests.

 Parkinson's is a neurological disorder of middle-aged and elderly people
characterized
 by hand tremors and muscle rigidity. The exact cause of the disease is not
known, but it
 is believed to be related to a decline in the activity of tyrosine
hydrolase, the enzyme
 that makes the neurotransmitter dopamine, and the death of brain cells.

 The strategy behind the new gene therapy is to introduce the gene for this
enzyme into
 the brain, so that the enzyme is synthesized, more dopamine is made and
the disease
 symptoms can be eased.

 For therapy, the gene is first inserted into an adenovirus, one of a group
that causes
 human respiratory diseases. This virus serves as the vector to get the
gene into glial
 cells, which are a type of brain cell that plays a supportive role in the
central nervous
 system. The transfected glial cells are then injected into the brain.

 To test the gene therapy, the team used model rats show symptoms like
those of
 Parkinson's, such as a tendency to move around in circles. Several days
after the
 transfected glial cells were injected into the brains of these rats, the
animals
 demonstrated 50% less circling behavior.

 Unfortunately, the relief was only temporary, ending after around six
weeks. However,
 the researchers think this was due to an immune-system reaction to the
injected cells.
 They believe it will be possible to improve the technique to prolong the
therapeutic
 effect.

 <<Nihon Keizai Shimbun, Inc. -- 02-23-98>>

 [Copyright 1998, Nikkei America]

John Stafford -- http://pw2.netcom.com/~johnws/index.html --
[log in to unmask]
................... Si fallatis officium, quaestor infinitius eat se
quicquam scire de factis vestris.